Clinical insight reveals significant improvement in refractory hypocalcaemia in neonates using teriparatide, suggesting advanced pharmacological agents may be effective.
Key Points
Refractory hypocalcaemia significantly improved with teriparatide therapy, showcasing new treatment options.
The case illustrates the use of a recombinant parathyroid hormone analogue in treating difficult neonatal conditions.
Most cases respond to standard treatment, yet some require advanced pharmacological agents like teriparatide.
Clinical manifestations of hypocalcaemia in neonates can include seizures, irritability, and arrhythmias.